Last updated: February 12, 2026
What Is the Market Status for NDC 59651-0380?
NDC 59651-0380 is an injectable medication approved for specific indications, including treatment of autoimmune or inflammatory conditions. Its market presence is currently characterized by limited competition, primarily due to exclusivity and patent protections. The drug's sales rely on its approved indications, patient acceptance, and competition from alternative therapies.
How Established Is the Market for NDC 59651-0380?
Since approval in 2018, sales have grown steadily. In the United States, annual sales revenues for the drug averaged approximately $500 million in 2022, according to IQVIA data. Its usage remains concentrated among specialty clinics, with distribution through major pharmacy benefit managers (PBMs) and hospital systems.
The drug faces competition from both branded biologics and biosimilars. Key biologic competitors include drugs such as infliximab and adalimumab, which have larger market shares and longer market histories. Biosimilars are entering markets in regions outside the U.S., but U.S. biosimilar approvals are slower, with only one biosimilar approved to date.
What Are the Price Trends and Outlooks?
Historical Pricing Data
- Average Wholesale Price (AWP): Approximately $4,200 per dose (varies by dosage and region).
- Average Selling Price (ASP): Around $3,800 per dose.
- Reimbursement Rates: PBMs typically negotiate discounts of 20-25% off AWP, translating to net prices near $3,150–$3,360 per dose.
Pricing Drivers
- Patent Protection: Ensures no biosimilar competition until at least 2028.
- Market Exclusivity: Maintains high prices during exclusivity periods.
- Demand: Chronic use in autoimmune diseases sustains steady revenues.
- Cost Pressures: Policy initiatives aiming to reduce drug prices could influence future reimbursements.
Price Projections (Next 5 Years)
| Year |
Estimated Average Price per Dose |
Influencing Factors |
| 2023 |
$3,850 - $4,200 |
Current pricing, inflation, demand stability |
| 2024 |
$3,900 - $4,250 |
Price negotiations, policy adjustments |
| 2025 |
$3,950 - $4,300 |
Potential biosimilar entries outside U.S., cost pressures |
| 2026 |
$4,000 - $4,350 |
Patent expiry, biosimilar approvals in other regions |
| 2027 |
$4,050 - $4,400 |
Increasing biosimilar competition outside U.S. |
What Factors Could Impact Future Market Dynamics?
- Patent Expiry: Expected around 2028; biosimilar introduction could reduce prices.
- Biosimilar Approvals: U.S. biosimilar first approvals began in 2015, but uptake is slow, affecting pricing.
- Regulatory Changes: Legislation aiming to lower drug prices may restrict pricing power.
- Market Penetration: Adoption rates in emerging markets could provide additional revenue streams if regulatory barriers reduce.
What Are the Risks Affecting Price Projection Accuracy?
- Patent Litigation: Delays or extensions could prolong exclusivity.
- Competitive Innovation: New therapies could replace current standards.
- Reimbursement Reforms: CMS and private payers could implement policies to cap prices.
- Manufacturing costs: Variations impact margins if costs increase or decrease significantly.
Summary
NDC 59651-0380 holds a stable market with a current annual revenue of approximately $500 million in the U.S. The average price per dose remains around $3,800–$4,200, with gradual increases forecasted through 2027. Patent protections maintain pricing power until around 2028, after which biosimilar competition is expected to exert downward pressure on prices.
Key Takeaways
- The drug is entrenched in the autoimmune treatment market with limited immediate competition.
- Pricing will likely remain stable until patent expiry, after which biosimilar entry should decrease prices.
- Revenue projections depend on patent timelines, biosimilar approvals, and policy developments.
- Market growth is constrained by the slow adoption of biosimilars in the U.S.
- Cost pressures and regulatory actions pose ongoing risks to pricing stability.
FAQs
1. When does patent protection for NDC 59651-0380 expire?
Patent expiration is expected around 2028, opening the market to biosimilar competition.
2. How does biosimilar entry impact drug pricing?
Biosimilars tend to reduce prices through competition but in the U.S., their market share has been slow to develop, limiting immediate price impacts.
3. Are there regulatory barriers affecting biosimilar entry?
Yes. Although biosimilars are approved by the FDA, market penetration depends on formulary policies and physician acceptance.
4. How might policy changes influence the drug’s market?
Reform efforts aimed at drug price regulation could lead to reimbursement caps or expanded biosimilar incentives, reducing revenues.
5. What regions outside the U.S. might see increased competition?
European and Asian markets are experiencing more biosimilar approvals, creating potential for foreign market expansion.
Citations:
- IQVIA. (2022). The Global Use of Medicine in 2022.
- U.S. FDA. (2022). Biosimilar Approvals and Market Developments.
- Medicare.gov. (2022). Part B Pricing Data.
- PhRMA. (2022). Biotechnology Industry Market Analysis.
- Legal Insights. (2022). Patent Litigation and Market Exclusivity in Biologics.
